Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Net Cash Flow (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Net Cash Flow for 9 consecutive years, with -$23.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 1321.47% year-over-year to -$23.9 million, compared with a TTM value of -$39.6 million through Dec 2025, down 157.62%, and an annual FY2025 reading of -$39.6 million, down 157.62% over the prior year.
  • Net Cash Flow was -$23.9 million for Q4 2025 at Puma Biotechnology, down from -$1.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $25.2 million in Q3 2022 and bottomed at -$25.9 million in Q3 2021.
  • Average Net Cash Flow over 5 years is -$3.3 million, with a median of -$3.8 million recorded in 2021.
  • The sharpest move saw Net Cash Flow plummeted 3078.04% in 2021, then soared 229.9% in 2023.
  • Year by year, Net Cash Flow stood at -$816000.0 in 2021, then plummeted by 115.56% to -$1.8 million in 2022, then skyrocketed by 229.9% to $2.3 million in 2023, then decreased by 14.4% to $2.0 million in 2024, then tumbled by 1321.47% to -$23.9 million in 2025.
  • Business Quant data shows Net Cash Flow for PBYI at -$23.9 million in Q4 2025, -$1.1 million in Q3 2025, and -$8.4 million in Q2 2025.